Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood diseases
Biotech
Takeda plays Protagonist, paying $300M for blood disease pact
Takeda is paying Protagonist Therapeutics $300 million upfront to develop and commercialize a late-stage rare hematology asset.
Gabrielle Masson
Jan 31, 2024 5:41pm
ASH: Pfizer swims in crowded sickle cell, hemophilia waters
Dec 9, 2023 7:00pm
Sickle cell gene therapy process may cause cancerous mutations
Nov 20, 2023 9:10am
One shot to cure sickle cell? Scientists give it a try with mRNA
Jul 28, 2023 11:12am
Rocket's hematology programs blast off toward regulators
May 19, 2023 11:01am
Hemab uses $135M series B to target neglected blood disorders
Feb 21, 2023 4:07am